CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
trametinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02296112
NCT02296112Phase 2Completed
CompareCT.gov

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations

Vanderbilt-Ingram Cancer Center·interventional·Posted Nov 20, 2014·Updated May 28, 2021

In Brief

A Phase 2 clinical trial evaluating trametinib, laboratory biomarker analysis, and 1 other intervention for Recurrent Melanoma and 3 related conditions. Completed, enrolled 9 participants across 4 sites.

Detailed Summary

This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), National Comprehensive Cancer Network

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 20, 2014
Enrollment StartJan 1, 2015
Primary CompletionAug 1, 2018
Study CompletionApr 16, 2021
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 11.6 years ago

Interventions

trametinibdrug

Given PO

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies